Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bridges

Showing results (341-350 of 403) with videos related to

Pageof 41
Sort By:
Bioorganic & Medicinal Chemistry Letters|September 21, 2011
Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071Evan P Lebois, Gregory J Digby, Douglas J Sheffler, et al.
ACS Medicinal Chemistry Letters|August 14, 2024
Discovery of VU6008677: A Structurally Distinct Tricyclic M<sub>4</sub> Positive Allosteric Modulator with Improved CYP450 ProfileRory A Capstick, Sean R Bollinger, Julie L Engers, et al.
Bioorganic & Medicinal Chemistry Letters|November 28, 2021
Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M<sub>4</sub> muscarinic acetylcholine receptorAaron M Bender, Trever R Carter, Matthew Spock, et al.
ACS Chemical Neuroscience|October 1, 2011
Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous systemEvan P Lebois, Thomas M Bridges, L Michelle Lewis, et al.
Chemmedchem|April 3, 2014
Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probePatrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|June 29, 2012
Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptorJames M Salovich, Paige N Vinson, Douglas J Sheffler, et al.
Archives of Environmental Contamination and Toxicology|March 18, 2005
Assessing contaminant sensitivity of endangered and threatened aquatic species: part I. Acute toxicity of five chemicalsF J Dwyer, F L Mayer, L C Sappington, et al.
Bioorganic & Medicinal Chemistry Letters|December 27, 2011
Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012Bruce J Melancon, Alexander P Lamers, Thomas M Bridges, et al.
The British Journal of Ophthalmology|May 11, 2021
Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical studyCarley M Bogan, Jessica V Kaczmarek, Janene M Pierce, et al.
Frontiers in Public Health|May 22, 2024
Communities organizing to promote equity: engaging local communities in public health responses to health inequities exacerbated by COVID-19-protocol paperChristina M Pacheco, Kristina M Bridges, Edward F Ellerbeck, et al.
Pageof 41

Showing results (341-350 of 403) with videos related to

Sort By:
Pageof 41
Bioorganic & Medicinal Chemistry Letters|September 21, 2011
Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071Evan P Lebois, Gregory J Digby, Douglas J Sheffler, et al.
ACS Medicinal Chemistry Letters|August 14, 2024
Discovery of VU6008677: A Structurally Distinct Tricyclic M<sub>4</sub> Positive Allosteric Modulator with Improved CYP450 ProfileRory A Capstick, Sean R Bollinger, Julie L Engers, et al.
Bioorganic & Medicinal Chemistry Letters|November 28, 2021
Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M<sub>4</sub> muscarinic acetylcholine receptorAaron M Bender, Trever R Carter, Matthew Spock, et al.
ACS Chemical Neuroscience|October 1, 2011
Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous systemEvan P Lebois, Thomas M Bridges, L Michelle Lewis, et al.
Chemmedchem|April 3, 2014
Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probePatrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|June 29, 2012
Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptorJames M Salovich, Paige N Vinson, Douglas J Sheffler, et al.
Archives of Environmental Contamination and Toxicology|March 18, 2005
Assessing contaminant sensitivity of endangered and threatened aquatic species: part I. Acute toxicity of five chemicalsF J Dwyer, F L Mayer, L C Sappington, et al.
Bioorganic & Medicinal Chemistry Letters|December 27, 2011
Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012Bruce J Melancon, Alexander P Lamers, Thomas M Bridges, et al.
The British Journal of Ophthalmology|May 11, 2021
Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical studyCarley M Bogan, Jessica V Kaczmarek, Janene M Pierce, et al.
Frontiers in Public Health|May 22, 2024
Communities organizing to promote equity: engaging local communities in public health responses to health inequities exacerbated by COVID-19-protocol paperChristina M Pacheco, Kristina M Bridges, Edward F Ellerbeck, et al.
Pageof 41